 Low-dose intermittent trimethoprim-sulfamethoxazole prevention Pneumocystis carinii pneumonia patients human immunodeficiency virus infection important role chemoprophylaxis prevention Pneumocystis carinii pneumonia PCP human immunodeficiency virus type HIV patients undisputed cost-effective regimen unknown experience hospitals New York City area low-dose intermittent therapy combination trimethoprim sulfamethoxazole PCP HIV-infected patients total months primary prophylaxis patients months secondary prophylaxis patients PCP patients zidovudine Adverse reactions trimethoprim-sulfamethoxazole primary secondary prophylaxis patients ineligible trimethoprim-sulfamethoxazole prophylaxis prior adverse drug reaction HIV-infected patients candidates long-term trimethoprim-sulfamethoxazole prophylaxis projected cost savings prophylaxis regimen US Public Health Service enormous